Mario Dicato

BAM3 Pavillon 2, 6A Rue Nicolas Ernest Barblé
Luxembourg, LU L1210, Luxembourg

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 97 publications

Antileukemic potential of methylated indolequinone MAC681 through immunogenic necroptosis and PARP1 degradation.

Antileukemic potential of methylated indolequinone MAC681 through immunogenic necroptosis and PARP1 degradation.

Journal: Biomarker research
Published: April 24, 2024

Enhancing personalized immune checkpoint therapy by immune archetyping and pharmacological targeting.

Enhancing personalized immune checkpoint therapy by immune archetyping and pharmacological targeting.

Journal: Pharmacological research
Published: April 22, 2023

ATP1A1/BCL2L1 predicts the response of myelomonocytic and monocytic acute myeloid leukemia to cardiac glycosides.

ATP1A1/BCL2L1 predicts the response of myelomonocytic and monocytic acute myeloid leukemia to cardiac glycosides.

Journal: Leukemia
Published: March 20, 2023

Marine Polyether Phycotoxin Palytoxin Induces Apoptotic Cell Death via Mcl-1 and Bcl-2 Downregulation.

Marine Polyether Phycotoxin Palytoxin Induces Apoptotic Cell Death via Mcl-1 and Bcl-2 Downregulation.

Journal: Marine drugs
Published: March 08, 2023

Assessment of Mitochondrial Cell Metabolism by Respiratory Chain Electron Flow Assays.

Assessment of Mitochondrial Cell Metabolism by Respiratory Chain Electron Flow Assays.

Journal: Methods in molecular biology (Clifton, N.J.)
Published: June 01, 2021

Phytochemical Screening and Antioxidant and Cytotoxic Effects of Acacia macrostachya.

Phytochemical Screening and Antioxidant and Cytotoxic Effects of Acacia macrostachya.

Journal: Plants (Basel, Switzerland)
Published: May 18, 2021

Anti-Leukemic Properties of Aplysinopsin Derivative EE-84 Alone and Combined to BH3 Mimetic A-1210477.

Anti-Leukemic Properties of Aplysinopsin Derivative EE-84 Alone and Combined to BH3 Mimetic A-1210477.

Journal: Marine drugs
Published: March 01, 2021

Susceptibility of multiple myeloma to B-cell lymphoma 2 family inhibitors.

Susceptibility of multiple myeloma to B-cell lymphoma 2 family inhibitors.

Journal: Biochemical pharmacology
Published: October 04, 2020

BH3 Mimetics in AML Therapy: Death and Beyond?

BH3 Mimetics in AML Therapy: Death and Beyond?

Journal: Trends in pharmacological sciences
Published: April 09, 2020

HDAC6-an Emerging Target Against Chronic Myeloid Leukemia?

HDAC6-an Emerging Target Against Chronic Myeloid Leukemia?

Journal: Cancers
Published: January 06, 2020

The HDAC6 inhibitor 7b induces BCR-ABL ubiquitination and downregulation and synergizes with imatinib to trigger apoptosis in chronic myeloid leukemia.

The HDAC6 inhibitor 7b induces BCR-ABL ubiquitination and downregulation and synergizes with imatinib to trigger apoptosis in chronic myeloid leukemia.

Journal: Pharmacological research
Published: November 10, 2019

Novel HDAC inhibitor MAKV-8 and imatinib synergistically kill chronic myeloid leukemia cells via inhibition of BCR-ABL/MYC-signaling: effect on imatinib resistance and stem cells.

Novel HDAC inhibitor MAKV-8 and imatinib synergistically kill chronic myeloid leukemia cells via inhibition of BCR-ABL/MYC-signaling: effect on imatinib resistance and stem cells.

Journal: Clinical epigenetics
Published: October 25, 2019
Showing 1-12 of 97

Last Updated: 09/26/2026